Dongsheng Wang

Dongsheng Wang

Auto-generated profile, based on publicly available information

Dongsheng Wang

The Second Affiliated Hospital of Dalian Medical University, Dalian, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
XXXiaoling Xu
Xiaoling Xu
MHMingfeng Han
Mingfeng Han
TLTiantian Li
Tiantian Li
WSWei Sun
Wei Sun
DWDongsheng Wang
Dongsheng Wang
HWHaiming Wei
Haiming Wei
Significance: In patients with coronavirus disease 2019, a large number of T lymphocytes and mononuclear macrophages are activated, producing cytokines such as interleukin-6 (IL-6), which bind to the IL-6 receptor on the target cells, causing the cytokine storm and severe inflammatory responses in lungs and other tissues and organs. Tocilizumab, as a recombinant humanized anti-human IL-6 receptor monoclonal antibody, can bind to the IL-6 receptor with high affinity, thus preventing IL-6 itself from binding to its receptor, rendering it incapable of immune damage to target cells, and alleviating the inflammatory responses.

13 October 2012 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
LHLi-Nian Huang
Li-Nian Huang
DWDong-Sheng Wang
Dong-Sheng Wang
YCYu-Qing Chen
Yu-Qing Chen
CZCheng-Ling Zhao
Cheng-Ling Zhao
BGBei-Lei Gong
Bei-Lei Gong
FHFeng-Dan Hu
Feng-Dan Hu

12 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XXXiaoling Xu
Xiaoling Xu
HWHaiming Wei
Haiming Wei
TLTiantian Li
Tiantian Li
WSWei Sun
Wei Sun
DWDongsheng Wang
Dongsheng Wang
HWHaiming Wei
Haiming Wei

17 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XXXiaoling Xu
Xiaoling Xu
HWHaiming Wei
Haiming Wei
TLTiantian Li
Tiantian Li
WSWei Sun
Wei Sun
DWDongsheng Wang
Dongsheng Wang
HWHaiming Wei
Haiming Wei

3 April 2023
Verified
Other
Open access
NJNing Jiang
Ning Jiang
DWDongsheng Wang
Dongsheng Wang
ZHZhongliang Hu
Zhongliang Hu
HSHyung Ju C. Shin
Hyung Ju C. Shin
GQGuoqing Qian
Guoqing Qian
Nabil SabaNabil Saba
Nabil Saba
PDF file - 520KB, Supplementary Figure 6. CM combination inhibits EGFR and HER3 signaling activation in vivo. Supplementary Figure 7. Inhibition of pHER3 and pAKT expression by CM combination.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
JWJie Wang
Jie Wang
BGBella Guo
Bella Guo
XZXiang Zhang
Xiang Zhang
XZXimeng Zhao
Ximeng Zhao
DWDongsheng Wang
Dongsheng Wang
TMtonghui ma
tonghui ma
Backgrounds: Germline gene alterations in gliomas play a significant role during malignant transformation of progenitor glial cells. Previous pan-caner studies suggested 6-10% of gliomas patients harboring germline gene mutations. However, these studies are limited to only known cancer predisposition genes and a small scale of gliomas patients. In this study, we performed a multi-canter, large scale study to investigate the contribution of germline gene alterations to LGG and HGG. Methods: Genomic DNA was extracted from white blood cells from 1006 LGG patients and 1578 HGG patients and was subjected to Next-generation sequencing with Onco PanScan. Pathogenic or likely pathogenic germline variants (PGVs) were identified in 150 putative cancer-predisposition genes according to ACGM guideline. Fisher’s exact test was used for the statistics analysis (two-sided). Results: We identified 54 PGVs in LGG patients and 112 PGVs in HGG patients which were located in 31 and 40 unique genes, respectively (Table 1). There was a significant difference between HGG and LGG in younger patients with germline gene mutations (A group, p < 0.001), while not in B and C group. The results indicated that the incidence rate of TP53 or MSH2 germline mutations in HGG patients was much higher than in LGG patient (p < 0.01), while a lower incidence rate of ERCC5 germline mutations was observed in HGG patients in comparison with LGG patients (p < 0.05). Conclusions: This study indicated a higher PGVs frequency in HGG than in LGG, especially in younger group. In addition, there is different contribution of germline gene alterations to risk the formation of LGG or HGG. It might aid in the early diagnosis of these patients and genetic counseling of their families. Informations of PGVs in LGG and HGG LGG HGG Numbers of mutation carriers Numbers of LGG Mutation rate Numbers of mutation carriers Numbers of HGG Mutation rate Age A: 0-30 years 14 a*** 292 4.1% 29 b*** 189 15.3% B: 31-55 years 30 554 5.4% 41 639 6.4% C: >55 years 10 160 6.3% 42 c*** 750 5.6% Total 54 1006 5.4% 112 1578 7.1% Gender Male 35 567 6.2% 65 935 7.0% Female 19 439 4.3% 50 643 7.8% Total 54 1006 5.4% 112 1578 7.1% Top ten of high mutation rate ERCC5*, MUTYH, BRCA2, CHEK2, WRN, PRSS1, MSH6, FANCD2, ERCC2, FANCA TP53**, MSH2**, BRCA2, NF1, RAD51D, MSH6, PRSS1, BUB1B, PDE11A, BLM Note: LGG 1, Low Grade Glioma; HGG 2, High Grade Glioma; aNumbers of mutation carriers in A group were statistical different in LGG and HGG patients; bNumbers of mutation carriers in A group and B group were statistical different in HGG patients; cNumbers of mutation carriers in A group and C group were statistical different in HGG patients; * p < 0.05; ** p < 0.01; *** p < 0.001 Citation Format: Jie Wang, Bella Guo, Xiang Zhang, Ximeng Zhao, Dongsheng Wang, Fei Sun, Tonghui Ma. Germline gene alterations in high grade and low grade gliomas: A multi-center, large scale study in China [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5875.